New Horizon Health Ltd
06606
Company Profile
Business description
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
Contact
400 Jiang’er Road
13th Floor, T1 Building
Binjiang District, Zhejiang
Hangzhou310052
CHNT: +86 57181107210
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
1,041
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,999.00 | 16.40 | -0.18% |
| CAC 40 | 7,771.97 | 89.99 | -1.14% |
| DAX 40 | 24,065.47 | 196.75 | -0.81% |
| Dow JONES (US) | 44,483.16 | 21.88 | 0.05% |
| FTSE 100 | 9,132.81 | 4.13 | -0.05% |
| HKSE | 24,773.33 | 403.60 | -1.60% |
| NASDAQ | 21,356.11 | 226.44 | 1.07% |
| Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
| NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
| S&P 500 | 6,400.69 | 37.79 | 0.59% |
| S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
| SSE Composite Index | 3,573.21 | 42.51 | -1.18% |